 CAMBRIDGE, Mass., Oct. 06, 2021 GLOBE NEWSWIRE -- Intellia Therapeutics, Inc. NASDAQ:NTLA, a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPRCas9 technology both in vivo and ex vivo, today announced the authorization of its Clinical Trial Application CTA by the New Zealand Medicines and Medical Devices Safety Authority MEDSAFE to initiate a Phase 12 study evaluating NTLA-2002 for the treatment of adults with hereditary angioedema HAE. HAE is a genetic disorder characterized by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating and life-threatening. NTLA-2002 is a systemically administered single-dose CRISPRCas9-based therapeutic candidate designed to inactivate the target gene Kallikrein B1 KLKB1 to permanently reduce plasma kallikrein activity and thus prevent HAE attacks. 